Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients

BACKGROUND: Several clinical studies have demonstrated that continuous administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could provide additional survival benefit for advanced non-small cell lung cancer (NSCLC) patients who had benefited from prior EGFR TKI th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Peng, Ling, Wang, Yina, Tang, Yemin, Zeng, Lei, Liu, Junfang, Zeng, Zhu, Liu, Jian, Shi, Peng, Ye, Xianghua, Zhao, Qiong
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584902/
https://ncbi.nlm.nih.gov/pubmed/28894381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S143569
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados